Sugi Predict

Sugi Predict / Compounds / P-Nitrophenol

P-Nitrophenol

P-Nitrophenol

SCHEMBL7526432

CCOP(=O)(O)OCC.O=[N+]([O-])c1ccc(O)cc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.64
▸ CA1 P00915 3/20 0.56
▸ CA2 P00918 2/20 0.56
▸ BCHE P06276 1/20 0.56
▸ ACHE P22303 1/20 0.56
▸ CES2 O00748 1/20 0.51
▸ CES1 P23141 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PTGS2 P35354 2/20 0.42
▸ BCL9 O00512 1/20 0.42
▸ CTNNB1 P35222 1/20 0.42
▸ PGK1 P00558 1/20 0.41
▸ PGK2 P07205 1/20 0.41
▸ PTGS1 P23219 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2545948 0.83 CES2 (0.73) AKR1C3CA1CA2BCHEACHE
SCHEMBL8093259 0.82 AKR1C3 (0.61) AKR1C3CA1CA2BCHEACHE
P-Nitrophenol SCHEMBL5807992 0.81 ALDH1A1 (0.48) AKR1C3CA1CA2BCHEACHE
P-Nitrophenol SCHEMBL9684585 0.81 CA1 (0.53) AKR1C3CA1CA2ACHECES2
P-Nitrophenol SCHEMBL28636238 0.80 HSD17B10 (0.54) AKR1C3CA1CA2ACHECES1
P-Nitrophenol SCHEMBL161007 0.80 CA1 (0.57) AKR1C3CA1CA2ACHECES2
P-Nitrophenol SCHEMBL28493361 0.80 CA1 (0.57) AKR1C3CA1CA2ACHECES2
SCHEMBL916414 0.79 CA1 (0.58) AKR1C3CA1CA2BCHEACHE
P-Nitrophenol SCHEMBL6681729 0.79 CA1 (0.55) AKR1C3CA1CA2ACHECES2
P-Nitrophenol SCHEMBL407205 0.79 CA1 (0.55) AKR1C3CA1CA2ACHECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062460-A1 METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS THERIPION, INC. (US) 2026-03-05 — — US disclosed
US-12509501-B2 Polynucleotides encoding APOA-1 fusion polypeptides THERIPION, INC. (US) 2025-12-30 — — US disclosed
US-12497604-B2 RNase-PON1 fusion polypeptides and related compositions and methods THERIPION, INC. (US) 2025-12-16 — — US disclosed
US-20250206806-A1 POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDES THERIPION, INC. (US) 2025-06-26 — — US disclosed
US-12331102-B2 APOA-1 fusion polypeptides and related compositions THERIPION, INC. (US) 2025-06-17 — — US disclosed
US-20250154484-A1 RNASE-PON1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS THERIPION, INC. (US) 2025-05-15 — — US disclosed
US-20250145977-A1 METHODS FOR TREATING RHEUMATOID ARTHRITIS USING CTLA4-PON1 FUSION PROTEINS THERIPION, INC. (US) 2025-05-08 — — US disclosed
US-12258596-B2 Polynucleotides encoding paraoxonase fusion polypeptides THERIPION, INC. (US) 2025-03-25 — — US disclosed
US-20250059525-A1 POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDES THERIPION, INC. (US) 2025-02-20 — — US disclosed
US-12180521-B2 Paraoxonase fusion polypeptides and related compositions and methods THERIPION, INC. (US) 2024-12-31 — — US disclosed
CN-111195531-B Hybrid material of multi-pyridine zinc complex modified MIL-101, preparation method and application of hybrid material in catalyzing degradation of organic phosphorus 安徽师范大学 2022-08-02 — — CN disclosed
US-20220089687-A1 POLYNUCLEOTIDES ENCODING APOA1-PON1 FUSION POLYPEPTIDES THERIPION INC (US) 2022-03-24 — — US disclosed
CN-111195531-A Hybrid material of multi-pyridine zinc complex modified MIL-101, preparation method and application of hybrid material in catalyzing degradation of organic phosphorus 安徽师范大学 2020-05-26 — — CN disclosed
CN-111195531-A Hybrid material of multi-pyridine zinc complex modified MIL-101, preparation method and application of hybrid material in catalyzing degradation of organic phosphorus 安徽师范大学 2020-05-26 — — CN disclosed
EP-3328881-B1 APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS THERIPION INC (US) 2019-08-28 — — EP disclosed
WO-2018136163-A2 TANDEM APOA-1 FUSION POLYPEPTIDES THERIPION, INC. (US) 2018-07-26 — — WO disclosed
US-20180201664-A1 APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS THERIPION, INC. 2018-07-19 — — US disclosed
EP-3328881-A1 APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS Theripion, Inc. (US) 2018-06-06 — — EP disclosed
WO-2017044424-A1 APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS THERIPION, INC. (US) 2017-03-16 — — WO disclosed
US-20020151068-A1 Compositions and methods for the diagnosis and treatment of organophosphate toxicity BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062460-A1 METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS PON1, APOB, APOL1 AKR1C3 1639/4885CA1 3122/4885CA2 3987/4885
US-12509501-B2 Polynucleotides encoding APOA-1 fusion polypeptides APOB, PON1, APOL1 AKR1C3 2142/4885CA1 3983/4885CA2 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.